--- title: "Protalix BioTherapeutics, Inc. (DE) (PLX) news: class action" url: "https://aibio.space/companies/protalix-biotherapeutics-de/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PLX class action and offering news: Protalix says Delaware stockholder class action over bylaws is dismissed, $160,000 in counsel fees." --- PLX Protalix BioTherapeutics, Inc. (DE) AMEX · United States # Protalix BioTherapeutics, Inc. (DE) (PLX) news PLX class action and offering news Financings · 2025-08-22 ## [Protalix renews $20,000,000 at-the-market stock program with H.C. Wainwright](https://aibio.space/news/protalix-renews-20-000-000-market-stock-program-h-c-wainwright/) About $15.7 million of stock remains available for sale after earlier sales of $4.3 million. The sales agent earns a 3.0% commission. ## Latest Protalix BioTherapeutics, Inc. (DE) news 1. 2025-08-01 Legal [Protalix says Delaware stockholder class action over bylaws is dismissed, $160,000 in counsel fees](https://aibio.space/news/protalix-says-delaware-stockholder-class-action-bylaws-dismissed-160/) A Delaware stockholder class action against Protalix BioTherapeutics and its board, Thomas v. Bashan, et al., was dismissed as to the plaintiff after the board amended the bylaws. Protalix agreed to pay $160,000 in fees and expenses to the plaintiff's counsel, and it denies the allegations. ## Protalix BioTherapeutics, Inc. (DE) at a glance - **Ticker**: PLX - **Listing**: AMEX - **Country**: United States - **Cash, Jun 30, 2026**: $27.4 million ### Related companies - [Ardelyx](https://aibio.space/companies/ardelyx/) NASDAQ: ARDX - [Eli Lilly](https://aibio.space/companies/eli-lilly/) NYSE: LLY - [Exelixis](https://aibio.space/companies/exelixis/) NASDAQ: EXEL - [Parabilis Medicines](https://aibio.space/companies/parabilis-medicines/) NASDAQ: PBLS - [Cerenome](https://aibio.space/companies/cerenome/) NASDAQ: CNSY - [Agios Pharmaceuticals](https://aibio.space/companies/agios-pharmaceuticals/) NASDAQ: AGIO - [Eledon Pharmaceuticals](https://aibio.space/companies/eledon-pharmaceuticals/) NASDAQ: ELDN - [Ligand Pharmaceuticals](https://aibio.space/companies/ligand-pharmaceuticals/) NASDAQ: LGND ### Also on AMEX - [Matinas Biopharma Holdings](https://aibio.space/companies/matinas-biopharma/) MTNB - [MAIA Biotechnology](https://aibio.space/companies/maia-biotechnology/) MAIA - [Regentis Biomaterials](https://aibio.space/companies/regentis-biomaterials/) RGNT - [Actinium Pharmaceuticals, Inc. (Delaware)](https://aibio.space/companies/actinium-pharmaceuticals-delaware/) ATNM - [Kairos Pharma](https://aibio.space/companies/kairos-pharma/) KAPA - [Oragenics](https://aibio.space/companies/oragenics/) OGEN ## What Protalix BioTherapeutics, Inc. (DE) does Protalix BioTherapeutics is a commercial stage biopharmaceutical company focused on the discovery, development, production and commercialization of therapeutics for rare diseases with significant unmet needs. Its proprietary ProCellEx plant cell-based protein expression system is used to manufacture its approved products and its pipeline candidates. The company's two commercial products are enzyme replacement therapies: Elelyso, for Gaucher disease, and Elfabrio, for Fabry disease. Elelyso was approved by the FDA in 2012 and is approved in more than 40 markets. Pfizer holds worldwide rights to commercialize Elelyso other than in Brazil, where Fiocruz markets it as BioManguinhos alfataliglicerase. In March 2026 the European Commission ratified a positive opinion approving the 2 mg/kg E4W dosing regimen of pegunigalsidase alfa for Fabry disease, after an appeal of an October 2025 negative opinion. The company is turning its focus to early-stage candidates for renal diseases and other high unmet need indications, including PEGylated uricase PRX-115 for uncontrolled gout, which is in a Phase 2 RELEASE study after a Phase 1 first-in-human trial, and long-acting DNase I PRX-119 for NETs-related diseases. | Product or program | What it is | Stage | |---|---|---| | Elelyso (taliglucerase alfa) | Plant cell-derived enzyme replacement therapy for Gaucher disease | approved in more than 40 markets | | Elfabrio (pegunigalsidase alfa) | Enzyme replacement therapy for adults with a confirmed diagnosis of Fabry disease | commercial product | | PRX-115 | PEGylated uricase for uncontrolled gout | Phase 2 (RELEASE), patients randomized | | PRX-119 | Long Acting DNase I for NETs-related diseases | | Summarised from the company's [10-K filed Mar 18, 2026](https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm). ## Protalix BioTherapeutics, Inc. (DE) annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$52.7 million](https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/) | [$53.4 million](https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/) | | Research and development | [$19.6 million](https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/) | [$13.0 million](https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/) | | Net income (loss) | [-$6.6 million](https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/) | [$2.9 million](https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/) | | Cash from operations | [-$12.0 million](https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/) | [$8.7 million](https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/) | | Cash and equivalents | [$14.7 million](https://www.sec.gov/Archives/edgar/data/1006281/000110465926094444/) | [$19.8 million](https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $27.4 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Analysis - Opinion Mixed view 2026-10-28 [Protalix has about a year of cash on paper. The second year is less clear.](https://aibio.space/analysis/protalix-has-about-year-cash-paper-second-year-less-clear/) Two approved drugs and an early pipeline. The company has $40.7 million and says that lasts 12 months, but its own filing lists 24 months of cash needs. Opinion, not personal investment advice. [All analysis](https://aibio.space/analysis/). ## Questions about Protalix BioTherapeutics, Inc. (DE) Is there a class action against Protalix BioTherapeutics, Inc. (DE)? Our latest story on this, dated Aug 1, 2025: "Protalix says Delaware stockholder class action over bylaws is dismissed, $160,000 in counsel fees". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/protalix-says-delaware-stockholder-class-action-bylaws-dismissed-160/). Has Protalix BioTherapeutics, Inc. (DE) raised money recently? Our latest story on this, dated Aug 22, 2025: "Protalix renews $20,000,000 at-the-market stock program with H.C. Wainwright". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/protalix-renews-20-000-000-market-stock-program-h-c-wainwright/). What is the ticker symbol of Protalix BioTherapeutics, Inc. (DE)? Protalix BioTherapeutics, Inc. (DE) trades under the ticker PLX on AMEX. Where is Protalix BioTherapeutics, Inc. (DE) listed? Protalix BioTherapeutics, Inc. (DE) is listed on AMEX. Our directory also records these other listings: GETTEX:PBDA; LSX:A2PWSL. What is the SEC CIK of Protalix BioTherapeutics, Inc. (DE)? The SEC Central Index Key (CIK) for Protalix BioTherapeutics, Inc. (DE) is 1006281. Its filings are on SEC EDGAR. How many shares does Protalix BioTherapeutics, Inc. (DE) have outstanding? 80,571,642 shares as of 2026-08-01, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Protalix BioTherapeutics, Inc. (DE) listed under? Our directory records Protalix BioTherapeutics, Inc. (DE) under United States. What does Protalix BioTherapeutics, Inc. (DE) do? Our directory classifies Protalix BioTherapeutics, Inc. (DE) as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Protalix BioTherapeutics, Inc. (DE)? The ISIN recorded for Protalix BioTherapeutics, Inc. (DE) is US74365A3095. Does aibio.space cover Protalix BioTherapeutics, Inc. (DE)? aibio.space lists Protalix BioTherapeutics, Inc. (DE) among 2,820 public biotech companies and publishes its news here as stories appear. Where is Protalix BioTherapeutics, Inc. (DE) incorporated? SEC records list its state or country of incorporation as DE. What does Protalix BioTherapeutics, Inc. (DE) develop? Protalix BioTherapeutics is a commercial stage biopharmaceutical company focused on the discovery, development, production and commercialization of therapeutics for rare diseases with significant unmet needs. Its proprietary ProCellEx plant cell-based protein expression system is used to manufacture its approved products and its pipeline candidates. What is Elelyso (taliglucerase alfa) from Protalix BioTherapeutics, Inc. (DE)? Elelyso (taliglucerase alfa): Plant cell-derived enzyme replacement therapy for Gaucher disease Stage: approved in more than 40 markets. What is Elfabrio (pegunigalsidase alfa) from Protalix BioTherapeutics, Inc. (DE)? Elfabrio (pegunigalsidase alfa): Enzyme replacement therapy for adults with a confirmed diagnosis of Fabry disease Stage: commercial product. What was Protalix BioTherapeutics, Inc. (DE)'s revenue last year? $52.7 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. ## Investor discussion: Protalix BioTherapeutics, Inc. (DE) Members talk about Protalix BioTherapeutics, Inc. (DE) (PLX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Protalix BioTherapeutics, Inc. (DE), newest first. Each line links the filing it comes from. 1. 2025-08-22 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1006281/000110465925081913/tm2523989d1_424b5.htm) 2. 2025-08-01 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1006281/000155837025009989/plx-20250801x8k.htm) 3. 2025-03-17 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1006281/000110465925024457/tm259263d1_424b5.htm) 4. 2024-12-23 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1006281/000155837024016445/plx-20241223xex99d1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open AMEX:PLX on TradingView](https://www.tradingview.com/symbols/AMEX-PLX/). ## SEC filings and registration - **SEC name**: Protalix BioTherapeutics, Inc. - **CIK**: 1006281 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: PLX (NYSE) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 2 UNIVERSITY PLAZA, HACKENSACK, NJ, 07601 - **Phone**: 201-696-9345 - **Shares outstanding**: 80,571,642 as of 2026-08-01 (10-Q filed 2026-08-12) - **Former names**: ORTHODONTIX INC; EMBASSY ACQUISITION CORP ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1006281/000110465926094444/plx-20260630x10q.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1006281/000110465926094433/plx-20260812x8k.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1006281/000110465926077790/plx-20260625x8k.htm) filed 2026-06-25 - [8-K](https://www.sec.gov/Archives/edgar/data/1006281/000110465926064850/plx-20260521x8k.htm) filed 2026-05-21 - [10-Q](https://www.sec.gov/Archives/edgar/data/1006281/000110465926059756/plx-20260331x10q.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1006281/000110465926059749/plx-20260513x8k.htm) filed 2026-05-13 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1006281/000110465926053016/plx-20260625xdef14a.htm) filed 2026-04-30 - [10-K](https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm) filed 2026-03-18 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001006281), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Protalix BioTherapeutics, Inc. (DE) is a public biotech or pharmaceutical company listed on AMEX under the ticker PLX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Protalix BioTherapeutics, Inc. (DE) - **Ticker**: PLX - **Listing**: AMEX - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US74365A3095 - **Other listed symbols**: GETTEX:PBDA; LSX:A2PWSL - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/AMEX-PLX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/protalix-biotherapeutics-de/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Protalix BioTherapeutics, Inc. (DE) (PLX) news: class action", 2026-10-31, https://aibio.space/companies/protalix-biotherapeutics-de/